Impact of liver fibrosis and clinical characteristics on dose-adjusted serum methadone concentrations
Permanent link
https://hdl.handle.net/10037/26201Date
2022-03-31Type
Journal articleTidsskriftartikkel
Peer reviewed
Author
Chalabianloo, Fatemeh; Høiseth, Gudrun; Vold, Jørn Henrik; Johansson, Kjell Arne; Kringen, Marianne K.; Dalgard, Olav; Ohldieck, Christian; Druckrey-Fiskaaen, Karl Trygve; Aas, Christer Frode; Løberg, Else-Marie; Bramness, Jørgen Gustav; Fadnes, Lars T.Abstract
Background: There is limited knowledge on the causes of large variations in serum
methadone concentrations and dose requirements.
Objectives: We investigated the impact of the degree of liver fibrosis on dose-adjusted
steady-state serum methadone concentrations.
Results: When adjusted for age, gender, body mass index, and genotypes of CYP2B6 and CYP3A5, the concentration-to-dose ratio of methadone did not increase among the participants with liver fibrosis (Coefficient: 0.70; 95% CI: −2.16, 3.57; P: 0.631), even among those with advanced cirrhosis (−0.50; −4.59, 3.59; 0.810).
Conclusions: Although no correlation was found between the degree of liver stiffness and dose-adjusted serum methadone concentration, close clinical monitoring should be considered, especially among patients with advanced cirrhosis. Still, serum methadone measurements can be considered a supplement to clinical assessments, taking into account intra-individual variations.
Publisher
Taylor & FrancisCitation
Chalabianloo, Høiseth, Vold, Johansson, Kringen, Dalgard, Ohldieck, Druckrey-Fiskaaen, Aas, Løberg, Bramness, Fadnes. Impact of liver fibrosis and clinical characteristics on dose-adjusted serum methadone concentrations. Journal of Addictive Diseases. 2022:1-12Metadata
Show full item recordCollections
Copyright 2022 The Author(s)